The ITP Natural History Study Registry: Preliminary Findings on the Immune Thrombocytopenia Patient Experience

DiscussionWe focused on general questions across surveys, especially on topics most important to ITP patients. Completion of surveys was hindered by the time and effort needed to answer survey questions. In the future, we hope that completion of the remaining surveys will continue, helping us to examine differences in disease experience across sub-populations. This overview will assist the ITP community with the development of recommendations for standards of care, assist researchers studying the pathophysiology of ITP and interventional outcomes, and support the design of clinical trials for new treatments.DisclosuresKruse: Amgen/ITP: Consultancy; Novartis/ITP: Consultancy; Rigel/ITP: Honoraria. Lambert: Educational Concepts in Medicine: Consultancy; Summus: Consultancy; Amgen: Membership on an entity's Board of Directors or advisory committees; Shionogi: Consultancy; Bayer: Membership on an entity's Board of Directors or advisory committees; Sysmex: Consultancy; Rigel: Consultancy; CSL: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees.
Source: Blood - Category: Hematology Authors: Tags: 311. Disorders of Platelet Number or Function Source Type: research